Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
April 4, 2022 06:37 AM EDTUpdated 10:50 AM
Pharma

No­var­tis CEO Vas Narasimhan re­struc­tures the phar­ma gi­ant, cut­ting costs $1B+, oust­ing top ex­ecs and sig­nal­ing lay­offs ahead

John Carroll

Editor & Founder

No­var­tis CEO Vas Narasimhan has a plan to make the glob­al phar­ma gi­ant more prof­itable. And he’s start­ing by carv­ing out a bil­lion dol­lars-plus in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

HHS can re­quire ap­proval for drug­mak­ers to ap­ply 340B re­bate mod­els, court rules

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

A service from the Financial Times